Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for REC-4881 in Familial Adenomatous Polyposis. The expected timing is based on the latest available company guidance and may change.
TUPELO trial. 11/6/24- Part 1 completed and Part 2 enrollment ongoing. 5/5/25- Presented preliminary data DDW 2025. 8/5/25- Additional data from FAP in H2 2025. 12/1/25- Present new clinical readout at company webinar on December 8, 2025. 12/08/25:- TUPELO Ph2 data showed durable polyp burden reductions and manageable safety. Plan FDA pathway meeting in H1 2026. 02/25/26:- TUPELO Ph2 showed durable polyp reductions with good safety. FDA engagement in H1 2026; more Ph1b/2 data H1 2027. 05/06/26:- TUPELO Ph2 showed durable polyp reductions; FDA engagement initiated. Regulatory update H2 2026; more Ph1b/2 data H1 2027. 08/05/26:- TUPELO Ph2 data presentation set for November 2, 2026. Registrational path update expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.